Journal article
A pilot dose finding study of pioglitazone in autistic children
Abstract
BackgroundPioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations.ObjectiveThis pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5–12 years old.MethodsWe conducted a 16-week prospective cohort, single blind, single …
Authors
Capano L; Dupuis A; Brian J; Mankad D; Genore L; Hastie Adams R; Smile S; Lui T; Odrobina D; Foster JA
Journal
Molecular Autism, Vol. 9, No. 1,
Publisher
Springer Nature
Publication Date
12 2018
DOI
10.1186/s13229-018-0241-5
ISSN
2040-2392